News coverage about Zai Lab (NASDAQ:ZLAB) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Zai Lab earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.8033042422959 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of ZLAB stock traded down $0.60 during trading hours on Monday, hitting $22.76. 4,122 shares of the company’s stock were exchanged, compared to its average volume of 102,686. The stock has a market capitalization of $1.18 billion and a PE ratio of -9.75. Zai Lab has a 52 week low of $17.85 and a 52 week high of $35.74.
A number of analysts have weighed in on the company. Leerink Swann reiterated an “outperform” rating on shares of Zai Lab in a research report on Friday, March 23rd. Zacks Investment Research upgraded Zai Lab from a “sell” rating to a “hold” rating in a research report on Thursday, June 7th. BidaskClub cut Zai Lab from a “buy” rating to a “hold” rating in a research report on Saturday, June 2nd. Finally, ValuEngine upgraded Zai Lab from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. Zai Lab presently has an average rating of “Hold” and an average target price of $37.50.
About Zai Lab
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics for oncology, and autoimmune and infectious disease therapies in China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor for the treatment of ovarian, breast, and lung cancers; ZL-2401, an antibiotic for the treatment of acute bacterial skin/skin structure infections, community-acquired bacterial pneumonias, and urinary tract infections; ZL-2301 that is Phase II clinical trial for the treatment of hepatocellular carcinoma; ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; ZL-2302 for the treatment of non-small cell lung cancer; and ZL-1101, an anti-OX40 antagonistic antibody for the treatment of graft-versus-host disease or systemic lupus erythematosus.
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.